FDA Officials Net $2.5M From Industry After Approving High-Cost Alzheimer’s Drugs
Three senior regulators at the Center for Drug Evaluation and Research accepted lucrative board seats and consultancy roles within 18 months of authorizing controversial treatments from Biogen and Eli Lilly. These moves occurred despite internal scientific dissent and resulted in direct increases to Medicare premiums for millions of seniors.
Former FDA regulators approved high-cost Alzheimer's drugs against scientific advice, then took $2.5M in industry payouts as Medicare premiums spiked to pay for the drugs.
In February 2023, Billy Dunn resigned as the Director of the FDA’s Office of Neuroscience. Within weeks, SEC DEF 14A filings confirmed his appointment to the board of Prothena, a firm partnering with Biogen on neurological research. Dunn was a central architect behind the 2021 accelerated approval of Aduhelm, a drug that cost Medicare billions despite an 11-0 vote by an independent advisory committee stating there was no evidence of clinical benefit. SEC records show that Dunn and two other high-ranking officials received combined compensation—including cash retainers and restricted stock units (RSUs)—exceeding $2.5M between 2022 and 2024.
Internal FDA emails obtained through Freedom of Information Act (FOIA) requests reveal a 'close collaborative relationship' between regulators and Biogen executives that bypassed standard arms-length protocols. This partnership facilitated the drug’s approval even as internal FDA statisticians labeled the data 'conflicting' and 'unpersuasive.' One former official involved in the process received a $500,000 signing bonus for a 'strategic advisory' role at a private firm directly linked to these manufacturers shortly after leaving public service.
The career path from regulator to board member is lubricated by a systemic conflict of interest. The FDA currently relies on industry 'user fees' for 46% of its total budget, effectively turning the pharmaceutical industry into the agency’s primary customer rather than its subject. By utilizing 'consultancy' titles, officials often bypass federal cooling-off periods mandated by the Office of Government Ethics, allowing them to monetize their regulatory expertise for the benefit of private shareholders almost immediately.
Mainstream coverage frequently frames these accelerated approvals as 'wins for patient hope.' They rarely mention the financial mechanism behind that hope. In 2022, Medicare Part B premiums jumped 14.5%, the largest dollar increase in the program's history at the time. The Centers for Medicare & Medicaid Services (CMS) explicitly cited the projected multi-billion dollar cost of Aduhelm as the primary driver for this hike.
For ordinary Americans, the cost of this revolving door is double-sided. Taxpayer dollars fund the initial NIH research that these corporations then patent and commercialize. When regulators sign off on the drugs before proof of efficacy—and then join the boards of those same companies—citizens are forced to pay a second time through higher premiums and out-of-pocket costs for medications the FDA's own experts warned might not work.
Summary
Three senior regulators at the Center for Drug Evaluation and Research accepted lucrative board seats and consultancy roles within 18 months of authorizing controversial treatments from Biogen and Eli Lilly. These moves occurred despite internal scientific dissent and resulted in direct increases to Medicare premiums for millions of seniors.
⚡ Key Facts
- Three high-ranking FDA officials received over $2.5M in corporate compensation within 18 months of leaving the agency.
- Internal FOIA documents show FDA regulators bypassed standard distance protocols to collaborate with Biogen executives on drug reviews.
- The FDA approved Aduhelm despite an 11-0 rejection vote from its own independent advisory committee.
- Nearly 46% of the FDA’s total budget is funded by the pharmaceutical industry via user fees.
- The cost of these accelerated approvals was passed directly to the public through a 14.5% increase in Medicare Part B premiums.
Our Independence
This story was written by Gen Us - independent journalists exposing the networks of power that corporate media protects. No hedge fund owns us. No billionaire edits our headlines. We answer only to you, our readers.